

# Ewing's Sarcoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/E2E24845C7C5EN.html>

Date: May 2024

Pages: 135

Price: US\$ 6,499.00 (Single User License)

ID: E2E24845C7C5EN

## Abstracts

The 7 major Ewing's sarcoma markets reached a value of US\$ 47.8 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 74.5 Million by 2034, exhibiting a growth rate (CAGR) of 4.1% during 2024-2034.

The Ewing's sarcoma market has been comprehensively analyzed in IMARC's new report titled "Ewing's Sarcoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Ewing's sarcoma is a rare type of oncological disease that affects primitive nerve tissue of bones or soft tissues surrounding the bones. It most commonly occurs in the long bones of the arms and legs but can also develop in the soft tissues of the limbs, chest, or abdomen. Individuals suffering from this condition may experience pain, tenderness or swelling near the affected area, bone pain, limping, extreme tiredness, fever with no known cause, unexplained weight loss, etc. The other infrequent symptoms include palpable soft-tissue mass, paralysis, loss of bladder control, and bone fractures. The diagnosis of Ewing's sarcoma is mainly made by reviewing the patient's underlying indications, medical history, and physical examination. Numerous other studies, like magnetic resonance imaging (MRI), computed tomography (CT) scans, positron emission tomography (PET) scans, etc., are also utilized to look for signs of bone damage. The healthcare provider may further perform a biopsy, which involves the removal of tiny samples of the affected region to examine it under a microscope and validate a diagnosis.

The increasing cases of genetic abnormalities that lead to the disruption of normal tissues and the formation of unhealthy cells throughout the body are primarily driving the Ewing's sarcoma market. In addition to this, the widespread adoption of radical

chemotherapy, which aims at complete irradiation of tumors, is also bolstering the market growth. Furthermore, the escalating demand for antisense oligodeoxynucleotide therapy to treat locally advanced disease conditions by down-regulating the expression of the oncogenic cellular RNA associated with the development of Ewing's sarcoma is acting as another significant growth-inducing factor. Additionally, the inflating utilization of proton beam radiation technique, which delivers an effective dose and controls damage to healthy tissues surrounding the cancerous cells, is further creating a positive outlook for the market. Apart from this, the emerging popularity of autologous stem cell transplantation as a viable treatment option owing to reduced metastasis and improved disease-free survival of patients, is expected to drive the Ewing's sarcoma market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the Ewing's sarcoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Ewing's sarcoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Ewing's sarcoma market in any manner.

#### Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

#### Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain  
Japan

### Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the Ewing's sarcoma market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the Ewing's sarcoma market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current Ewing's sarcoma marketed drugs and late-stage pipeline drugs.

### In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

### Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

\*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the Ewing's sarcoma market performed so far and how will it perform in the

coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the Ewing's sarcoma market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the Ewing's sarcoma market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

## Epidemiology Insights

What is the number of prevalent cases (2018-2034) of Ewing's sarcoma across the seven major markets?

What is the number of prevalent cases (2018-2034) of Ewing's sarcoma by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of Ewing's sarcoma by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with Ewing's sarcoma across the seven major markets?

What is the size of the Ewing's sarcoma patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of Ewing's sarcoma?

What will be the growth rate of patients across the seven major markets?

## Ewing's Sarcoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for Ewing's sarcoma drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Ewing's sarcoma market?

What are the key regulatory events related to the Ewing's sarcoma market?

What is the structure of clinical trial landscape by status related to the Ewing's sarcoma market?

What is the structure of clinical trial landscape by phase related to the Ewing's sarcoma market?

What is the structure of clinical trial landscape by route of administration related to the Ewing's sarcoma market?

## Contents

### **1 PREFACE**

### **2 SCOPE AND METHODOLOGY**

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
  - 2.3.1 Primary Sources
  - 2.3.2 Secondary Sources
- 2.4 Market Estimation
  - 2.4.1 Bottom-Up Approach
  - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

### **3 EXECUTIVE SUMMARY**

### **4 EWING'S SARCOMA - INTRODUCTION**

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

### **5 EWING'S SARCOMA - DISEASE OVERVIEW**

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

### **6 PATIENT JOURNEY**

### **7 EWING'S SARCOMA - EPIDEMIOLOGY AND PATIENT POPULATION**

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
  - 7.2.1 Epidemiology Scenario (2018-2023)
  - 7.2.2 Epidemiology Forecast (2024-2034)
  - 7.2.3 Epidemiology by Age (2018-2034)
  - 7.2.4 Epidemiology by Gender (2018-2034)
  - 7.2.5 Diagnosed Cases (2018-2034)
  - 7.2.6 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
  - 7.3.1 Epidemiology Scenario (2018-2023)
  - 7.3.2 Epidemiology Forecast (2024-2034)
  - 7.3.3 Epidemiology by Age (2018-2034)
  - 7.3.4 Epidemiology by Gender (2018-2034)
  - 7.3.5 Diagnosed Cases (2018-2034)
  - 7.3.6 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
  - 7.4.1 Epidemiology Scenario (2018-2023)
  - 7.4.2 Epidemiology Forecast (2024-2034)
  - 7.4.3 Epidemiology by Age (2018-2034)
  - 7.4.4 Epidemiology by Gender (2018-2034)
  - 7.4.6 Diagnosed Cases (2018-2034)
  - 7.4.7 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
  - 7.5.1 Epidemiology Scenario (2018-2023)
  - 7.5.2 Epidemiology Forecast (2024-2034)
  - 7.5.3 Epidemiology by Age (2018-2034)
  - 7.5.4 Epidemiology by Gender (2018-2034)
  - 7.5.5 Diagnosed Cases (2018-2034)
  - 7.5.6 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
  - 7.6.1 Epidemiology Scenario (2018-2023)
  - 7.6.2 Epidemiology Forecast (2024-2034)
  - 7.6.3 Epidemiology by Age (2018-2034)
  - 7.6.4 Epidemiology by Gender (2018-2034)
  - 7.6.5 Diagnosed Cases (2018-2034)
  - 7.6.6 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
  - 7.7.1 Epidemiology Scenario (2018-2023)
  - 7.7.2 Epidemiology Forecast (2024-2034)
  - 7.7.3 Epidemiology by Age (2018-2034)

- 7.7.4 Epidemiology by Gender (2018-2034)
- 7.7.5 Diagnosed Cases (2018-2034)
- 7.7.6 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
  - 7.8.1 Epidemiology Scenario (2018-2023)
  - 7.8.2 Epidemiology Forecast (2024-2034)
  - 7.8.3 Epidemiology by Age (2018-2034)
  - 7.8.4 Epidemiology by Gender (2018-2034)
  - 7.8.5 Diagnosed Cases (2018-2034)
  - 7.8.6 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
  - 7.9.1 Epidemiology Scenario (2018-2023)
  - 7.9.2 Epidemiology Forecast (2024-2034)
  - 7.9.3 Epidemiology by Age (2018-2034)
  - 7.9.4 Epidemiology by Gender (2018-2034)
  - 7.9.5 Diagnosed Cases (2018-2034)
  - 7.9.6 Patient Pool/Treated Cases (2018-2034)

## **8 EWING'S SARCOMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES**

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

## **9 EWING'S SARCOMA - UNMET NEEDS**

## **10 EWING'S SARCOMA - KEY ENDPOINTS OF TREATMENT**

## **11 EWING'S SARCOMA - MARKETED PRODUCTS**

- 11.1 List of Ewing's Sarcoma Marketed Drugs Across the Top 7 Markets
  - 11.1.1 Drug Name – Company Name
    - 11.1.1.1 Drug Overview
    - 11.1.1.2 Mechanism of Action
    - 11.1.1.3 Regulatory Status
    - 11.1.1.4 Clinical Trial Results
    - 11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.



## **12 EWING'S SARCOMA - PIPELINE DRUGS**

### 12.1 List of Ewing's Sarcoma Pipeline Drugs Across the Top 7 Markets

#### 12.1.1 Lurbinectedin - PharmaMar

##### 12.1.1.1 Drug Overview

##### 12.1.1.2 Mechanism of Action

##### 12.1.1.3 Clinical Trial Results

##### 12.1.1.4 Safety and Efficacy

##### 12.1.1.5 Regulatory Status

#### 12.1.2 Vigil - Gradalis

##### 12.1.2.1 Drug Overview

##### 12.1.2.2 Mechanism of Action

##### 12.1.2.3 Clinical Trial Results

##### 12.1.2.4 Safety and Efficacy

##### 12.1.2.5 Regulatory Status

#### 12.1.3 Seclidemstat - Salarius Pharmaceuticals

##### 12.1.3.1 Drug Overview

##### 12.1.3.2 Mechanism of Action

##### 12.1.3.3 Clinical Trial Results

##### 12.1.3.4 Safety and Efficacy

##### 12.1.3.5 Regulatory Status

#### 12.1.4 Eribulin mesylate - Eisai Co Ltd

##### 12.1.4.1 Drug Overview

##### 12.1.4.2 Mechanism of Action

##### 12.1.4.3 Clinical Trial Results

##### 12.1.4.4 Safety and Efficacy

##### 12.1.4.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

## **13. EWING'S SARCOMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS**

## **14. EWING'S SARCOMA – CLINICAL TRIAL LANDSCAPE**

### 14.1 Drugs by Status

### 14.2 Drugs by Phase

### 14.3 Drugs by Route of Administration

### 14.4 Key Regulatory Events

## **15 EWING'S SARCOMA - MARKET SCENARIO**

### 15.1 Market Scenario - Key Insights

### 15.2 Market Scenario - Top 7 Markets

#### 15.2.1 Ewing's Sarcoma - Market Size

##### 15.2.1.1 Market Size (2018-2023)

##### 15.2.1.2 Market Forecast (2024-2034)

#### 15.2.2 Ewing's Sarcoma - Market Size by Therapies

##### 15.2.2.1 Market Size by Therapies (2018-2023)

##### 15.2.2.2 Market Forecast by Therapies (2024-2034)

### 15.3 Market Scenario - United States

#### 15.3.1 Ewing's Sarcoma - Market Size

##### 15.3.1.1 Market Size (2018-2023)

##### 15.3.1.2 Market Forecast (2024-2034)

#### 15.3.2 Ewing's Sarcoma - Market Size by Therapies

##### 15.3.2.1 Market Size by Therapies (2018-2023)

##### 15.3.2.2 Market Forecast by Therapies (2024-2034)

#### 15.3.3 Ewing's Sarcoma - Access and Reimbursement Overview

### 15.4 Market Scenario - Germany

#### 15.4.1 Ewing's Sarcoma - Market Size

##### 15.4.1.1 Market Size (2018-2023)

##### 15.4.1.2 Market Forecast (2024-2034)

#### 15.4.2 Ewing's Sarcoma - Market Size by Therapies

##### 15.4.2.1 Market Size by Therapies (2018-2023)

##### 15.4.2.2 Market Forecast by Therapies (2024-2034)

#### 15.4.3 Ewing's Sarcoma - Access and Reimbursement Overview

### 15.5 Market Scenario - France

#### 15.5.1 Ewing's Sarcoma - Market Size

##### 15.5.1.1 Market Size (2018-2023)

##### 15.5.1.2 Market Forecast (2024-2034)

#### 15.5.2 Ewing's Sarcoma - Market Size by Therapies

##### 15.5.2.1 Market Size by Therapies (2018-2023)

##### 15.5.2.2 Market Forecast by Therapies (2024-2034)

#### 15.5.3 Ewing's Sarcoma - Access and Reimbursement Overview

### 15.6 Market Scenario - United Kingdom

#### 15.6.1 Ewing's Sarcoma - Market Size

##### 15.6.1.1 Market Size (2018-2023)

##### 15.6.1.2 Market Forecast (2024-2034)

- 15.6.2 Ewing's Sarcoma - Market Size by Therapies
  - 15.6.2.1 Market Size by Therapies (2018-2023)
  - 15.6.2.2 Market Forecast by Therapies (2024-2034)
- 15.6.3 Ewing's Sarcoma - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
  - 15.7.1 Ewing's Sarcoma - Market Size
    - 15.7.1.1 Market Size (2018-2023)
    - 15.7.1.2 Market Forecast (2024-2034)
  - 15.7.2 Ewing's Sarcoma - Market Size by Therapies
    - 15.7.2.1 Market Size by Therapies (2018-2023)
    - 15.7.2.2 Market Forecast by Therapies (2024-2034)
  - 15.7.3 Ewing's Sarcoma - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
  - 15.8.1 Ewing's Sarcoma - Market Size
    - 15.8.1.1 Market Size (2018-2023)
    - 15.8.1.2 Market Forecast (2024-2034)
  - 15.8.2 Ewing's Sarcoma - Market Size by Therapies
    - 15.8.2.1 Market Size by Therapies (2018-2023)
    - 15.8.2.2 Market Forecast by Therapies (2024-2034)
  - 15.8.3 Ewing's Sarcoma - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
  - 15.9.1 Ewing's Sarcoma - Market Size
    - 15.9.1.1 Market Size (2018-2023)
    - 15.9.1.2 Market Forecast (2024-2034)
  - 15.9.2 Ewing's Sarcoma - Market Size by Therapies
    - 15.9.2.1 Market Size by Therapies (2018-2023)
    - 15.9.2.2 Market Forecast by Therapies (2024-2034)
  - 15.9.3 Ewing's Sarcoma - Access and Reimbursement Overview

## **16 EWING'S SARCOMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS**

## **17 EWING'S SARCOMA MARKET - SWOT ANALYSIS**

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

## **18 EWING'S SARCOMA MARKET – STRATEGIC RECOMMENDATIONS**

## **19 APPENDIX**

## I would like to order

Product name: Ewing's Sarcoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/E2E24845C7C5EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E2E24845C7C5EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

